In this context, changes in BA composition could also be one reason for altered intestinal FXR signaling, expressed as reduced FGF19 levels, in our overweight and obese NAFLD patients. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.